Familial Hemiplegic Migraine Treatments

Find Familial Hemiplegic Migraine Treatments

Generic Name

Ondansetron

Brand Names

Ondansetron ODT, Sumansetron

FDA approval date: November 07, 2006

Classification: Serotonin-3 Receptor Antagonist

Form: Injection, Tablet, Kit, Solution

What is Ondansetron ODT (Ondansetron)?

1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥ 50 mg/m 2. 2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. 3. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. 4. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ondansetron orally disintegrating tablets are recommended even where the incidence of postoperative nausea and/or vomiting is low.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section: A Randomized Controlled Trial

Enrollment Status: Recruiting

Publish Date: April 14, 2026

Intervention Type: Drug

Study Phase: Not Applicable

Summary: This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in cesarean section (CS).

Prospective Randomized Controlled Study of Individualized PCA Model Based on Multi-dimensional Strategies (Fixed-rate Basal Infusion Mode and Time-programmed Decremental Background Infusion Mode)

Enrollment Status: Recruiting

Publish Date: April 06, 2026

Intervention Type: Procedure

Study Phase: Not Applicable

Summary: Perioperative pain management affects patient recovery. However, the rate of moderate to severe postoperative pain is as high as 73.8%, which hinders recovery and increases the risk of complications. Although opioids are the first-line analgesics, excessive use leads to adverse reactions. The traditional fixed-rate PCA mode is difficult to match the changes in postoperative pain. This study will c...

Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome: a Multicentre, Randomized, Double-blind, Parallel-group, Placebo-controlled Study

Enrollment Status: Recruiting

Publish Date: April 03, 2026

Intervention Type: Device, Drug

Study Phase: Not Applicable

Summary: Irritable Bowel Syndrome (IBS) is one of the major Disorders of Gut-Brain Interaction (DGBI) and the most frequent reasons for referral to both primary care providers and gastroenterologists.IBS is not a life-threatening disease, but imposes a significant burden on society, entailing a decrease in patients' Quality of Life (QoL), elevated rates of psychological comorbidities and loss of work produ...

View All Clinical Trials